Annovis Bio, Inc. · NYSE:ANVS
Annovis Bio — Corporate Update (June 2024)
15 slides from Annovis Bio's corporate update, Jun 11, 2024
Slide 1: Investor Webcast 6/11/2024
Investor Webcast 6/11/2024 NYSE: ANVS - People Focused, Purpose Driven, Passion Powered -
Slide 2: Forward-Looking Statements and Other Important Cautions
FORWARD - LOOKING STATEMENTS Forward Looking Statements and Other Important Cautions -- This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . These forward - looking statements relate to all information other than histori
Slide 3: Today's Presentation
3 » Study design » Primary endpoint results in ITT population » Subgroup analysis based on biomarker and MMSE scores » ADAScog11 in early AD patients » Subgroup analysis based on APOE status » ADAScog11 in APOE4 carriers/non - carriers » Safety in early AD patients, APOE4 carriers/non - carriers Tod
Slide 4: Randomized, double-blind, placebo-controlled dose-ranging study in mild to moderate Alzheimer's patients
4 RANDOMIZED, DOUBLE - BLIND, PLACEBO - CONTROLLED, DOSE - RANGING, MULTICENTER STUDY IN MILD TO MODERATE ALZHEIMER’S PATIENTS R 1:1:1:1 Placebo QD 7.5mg Buntanetap QD 15mg Buntanetap QD 30mg Buntanetap QD 6 weeks screening 12 weeks treatment N=80 N=80 N=80 N=80 N=320 Key Inclusion Criteria: • Diagn
Slide 5: Primary endpoint in ITT population (N=351)
5 PRIMARY ENDPOINT IN ITT POPULATION (N=351) ADAS - Cog11 Placebo (N=89) 7.5mg Buntanetap (N=88) 15mg Buntanetap (N=87) 30mg Buntanetap (N=87) Baseline N 85 86 87 87 Mean Score (SD) 20.28 (6.79) 23.20 (7.59) 22.74 (7.57) 21.85 (7.16) End of Trial (12 weeks) N 81 82 78 79 Mean Score (SD) 18.33 (6.94)
Slide 6: Biomarker based patient stratification
6 BIOMARKER BASED PATIENT STRATIFICATION (pTau217/ tTau >4.2%, N=210) MMSE 21 - 24 BASED PATIENT STRATIFICATION, N=90 Placebo (N=89) 7.5mg Buntanetap (N=88) 15mg Buntanetap (N=87) 30mg Buntanetap (N=87) ITT N 85 86 87 87 AD (pTau217/ tTau >4.2%) N 51 57 51 51 AD MMSE 14 - 20 25 36 26 25 AD MMSE 21 -
Slide 7: ADAScog11 in AD patients
7 Improve Buntanetap statistically and clinically significantly improved ADAS - Cog11 in patients with mild AD -4 -3 -2 -1 0 1 2 ADAS-Cog11 (pTau217/tTau>4.2% & MMSE16-20) D i f f e r e n c e b e t w e e n E O T a n d B a s e l i n e Placebo 7.5mg 15mg 30mg -6 -4 -2 0 2 ADAS-Cog11 (pTau217/tTau>4.2%
Slide 8: Subgroup analysis based on APOE status
8 SUBGROUP ANALYSIS BASED ON APOE STATUS EARLY AD PATIENTS N=90 APOE4 CARRIERS N=66; NON - CARRIERS N=24 Placebo 7.5mg Buntanetap 15mg Buntanetap 30mg Buntanetap AD (pTau217/ tTau >4.2%) MMSE21 - 24 21 20 24 25 AD MMSE 21 - 24 ApoE4 carriers 16 17 15 18 AD MMSE 21 - 24 Non ApoE4 carriers 5 3 9 7
Slide 9: ADAScog11 and APOE4 status
9 ADAScog11 AND APOE4 STATUS ApoE4 carrier (+/ - & +/+) 66.5% in pTau217/tTau>4.2% population vs ApoE4 carrier 22.6% in pTau217/tTau<4.2% population Buntanetap improves ADAS - Cog11 equally in APOE4 carriers and non - carriers
Slide 10: Safe in APOE4 carriers and non-carriers in ITT population and early AD patients
10 SAFE IN APOE4 CARRIERS AND NON - CARRIERS IN ITT POPULATION AND EARLY AD PATIENTS Placebo 7.5mg Buntanetap 15mg Buntanetap 30mg Buntanetap All Doses APOE Carriers (N=159) 38 45 38 38 121 # TEAEs 13 (34.2%) 22 (48.9%) 17 (44.7%) 12 (31.6%) 51 (42%) # TEAEs Related to Study Drug 1 (2.6%) 8 (17.8%)
Slide 11: Comparison with approved AD drugs
11 COMPARISON WITH APPROVED AD DRUGS - Aricept is a SYMPTOMATIC approved drug: it improves cognition by - 1.5 points at 3 months and - 2 points at 6 months. After that the efficacy wanes. - Leqembi is a DISEASE - MODIFYING drug: it does not improve the symptoms; in fact, at 3 months there is no diff
Slide 12: Disease modification versus symptomatic benefit in the treatment of Alzheimer's
12 DISEASE MODIFICATION VERSUS SYMPTOMATIC BENEFIT IN THE TREATMENT OF ALZHEIMER’S Onset of illness Death Quality of Life/Cognition Kennedy GJ. Primary Psychiatry. Vol 14. No 11. 2007, adapted Annovis No effect or placebo Disease modification - slow Disease modification - stop Symptomatic benefit Tr
Slide 13: Development of buntanetap for early AD
13 DEVELOPMENT OF BUNTANETAP FOR EARLY AD 3 - Month Symptomatic Study 6 - Month Symptomatic/ 18 - Month Disease - Modifying Study Mild - Moderate AD NDA Symptomatic Long acute/chronic study in early AD Open label study for all AD patients NDA Disease - Modifying
Slide 14: Q&A Session
14 NYSE: ANVS Q&A Session CONTACT US 101 Lindenwood Drive Malvern, PA 19355 ir@annovisbio.com www.annovisbio.com
Slide 15: Thank You for Your Support
15 NYSE: ANVS Thank You for Your Support CONTACT US 101 Lindenwood Drive Malvern, PA 19355 ir@annovisbio.com www.annovisbio.com